Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2011 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 4.8%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 4.8% following the earnings report, likely due to a lack of revenue information and no updated guidance. Investors may be concerned about the company's future performance without clearer direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.31	N/A	+14.60%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their product pipeline. They acknowledged the challenges but emphasized their commitment to innovation.

Management highlighted ongoing progress in their pipeline.

They expressed confidence in future developments despite current challenges.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 4.8%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 4.8%

Key numbers

Management commentary